Contact Us
Drug Search Results
More Filters [+]

Adebrelimab

Alternative Names: Adebrelimab, shr-1316, shr1316, shr 1316, hti-1088, hti1088
Latest Update: 2024-11-22
Latest Update Note: Clinical Trial Update

Product Description

SHR-1316 is a humanized IgG4 monoclonal antibody that binds specifically to human PD-L1.

Mechanisms of Action: PD-L1 Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Jiangsu Hengrui Medicine Co
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Adebrelimab

Countries in Clinic: Australia, China, Unknown Location

Active Clinical Trial Count: 33

Highest Development Phases

Phase 3: Hepatocellular Carcinoma|Non-Small-Cell Lung Cancer|Small Cell Lung Cancer|Squamous Cell Carcinoma

Phase 2: Adenocarcinoma|Biliary Tract Cancer|Breast Cancer|Bronchogenic Carcinoma|Cervical Cancer|Cholangiocarcinoma|Colorectal Cancer|Esophageal Cancer|Gastrointestinal Cancer|Male Breast Cancer|Oncology Solid Tumor Unspecified|Pancreatic Cancer|Uterine Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
SHR-1316-307

P3

Not yet recruiting

Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma

2028-10-01

LungMate-015

P3

Not yet recruiting

Small Cell Lung Cancer

2027-08-01

SHR-8068-201-BTC

P2

Recruiting

Biliary Tract Cancer

2026-12-30

23-OBU-FJ-HCC-II-012

P2

Recruiting

Hepatocellular Carcinoma

2026-11-15

Recent News Events

Date

Type

Title

05/06/2024

PubMed

 Population pharmacokinetics of adebrelimab - Support of alternative flat dose regimen in extensive-stage small-cell lung cancer.

04/16/2024

PubMed

 Efficacy and safety of novel immune checkpoint inhibitor-based combinations versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer: A network meta-analysis.

04/05/2024

PubMed

 Updated cost-effectiveness analysis of adebrelimab plus chemotherapy for extensive-stage small cell lung cancer in China.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions